Context Obesity impacts both individual health and, given its high prevalence, total health care spending. However, as medical technology evolves, health outcomes for a number of obesity-related illnesses improve. This article examines whether medical innovation can mitigate the adverse health and spending associated with obesity, using statins as a case study. Because of the relationship between obesity and hypercholesterolaemia, statins play an important role in the medical management of obese individuals and the prevention of costly obesity-related sequelae. Methods Using well-recognized estimates of the health impact of statins and the Future Elderly Model (FEM)-an established dynamic microsimulation model of the health of Americans aged over 50 years-we estimate the changes in life expectancy, functional status and health care costs of obesity due to the introduction and widespread use of statins. Results Life expectancy gains of statins are estimated to be 5-6 % greater for obese individuals than for healthyweight individuals, but most of these additional gains are associated with some level of disability. Considering both medical spending and the value of quality-adjusted lifeyears, statins do not significantly alter the costs of class 1 and 2 obesity (body mass index [BMI] C30 and C35 kg/ m 2 , respectively) and they increase the costs of class 3 obesity (BMI C40 kg/m 2 ) by 1.2 %.
The current use of statins is estimated to increase the life expectancy of 51-year-old Americans by about 1 year. Life expectancy gains are estimated to be 5-6 % higher for obese individuals. However, most of the additional gains are associated with some level of disability.
By extending longevity, statins increase the expected lifetime medical costs for 51-year-old Americans by about $25,000. The increase in medical costs is estimated to be $2,800-$4,000 greater for obese individuals.
Considering both medical spending and the value of quality-adjusted life-years, statins do not significantly alter the costs of class 1 and 2 obesity (body mass index [BMI] C30 and 35 kg/m 2 , respectively) and they increase the costs of class 3 obesity (BMI C40 kg/m 2 ) by 1.2 %.
Although statins are inexpensive and very effective medications for lowering the risk of obesityassociated illnesses, they do not significantly reduce the costs of obesity. This highlights the importance of preventing obesity, rather than treating its consequences.
Introduction
Between 1960 and 2002, the average height of American adults increased by approximately 1 inch (2.5 cm), while the average weight increased by over 24 pounds (11 kg) [1] . As a result, during those four decades, the prevalence of obesity (body mass index 1 [BMI] C30 kg/ m 2 ) more than doubled and the prevalence of extreme obesity (BMI C40 kg/m 2 ) increased sixfold. As of 2010, 36.1 % of American adults were obese and 6.6 % were extremely obese. A similar trend was apparent among men and women, most racial subgroups and the elderly [1] .
This increase in the prevalence of obesity is a serious concern from both a public health perspective and a fiscal perspective. Obesity is associated with increased risks of type II diabetes, ischaemic heart disease, ischaemic stroke, hypertension, dyslipidaemia, osteoarthritis and several cancers [2] . Published estimates of the health care costs attributable to obesity have consistently increased as the epidemic has grown [3] [4] [5] [6] . Finkelstein et al. [5] found-after adjustment for demographic factors, economic factors, and smoking status-that obese individuals incurred 42 % more direct medical costs. This translated into roughly 9.1 % of all public and private health care spending, or about $147 billion in 2006-with roughly one quarter paid for by Medicare [5] . Given the fact that most obesity-associated diseases do not present themselves until later adulthood, this finding is not surprising. However, it does underscore the importance of tackling the obesity epidemic in the aging population of the USA.
The past decades have also seen numerous medical innovations, several of which have become important components of the management of obesity-associated illnesses. However, little is known about how these innovations affect the health and health care costs of obesity.
In this study, we use the introduction of statins as a case study to shed light on this issue. Statins offer an interesting example for several reasons. First, statins are perhaps one of the most important innovations in recent medical history. Not only do they lower the risk of death from obesity-associated illness, they also lower the risk of developing some of these diseases in the first place [7] [8] [9] [10] [11] [12] . Second, statin use has increased rapidly since 2000, with more than 40 million adult Americans filling a prescription in 2011. 2 A recent study found a large social value for this widespread use and suggested that it may have prevented as many as 40,000 deaths and 100,000 hospitalizations for heart attacks and strokes in 2008 alone [13] . Third, statins are well studied, allowing us to model the effects of statins on long-term health outcome and health care costs.
We note that other examples of medical innovations, such as bariatric surgery and prescription weight loss drugs, directly reduce the weight of obese people. The former was shown to be quite effective [14] but has recently plateaued around 120,000 procedures per year [15] . Statin therapy differs from such innovations in that it is so widely used that it may plausibly have had a noticeable impact on the costs of obesity. We also believe that statins are a better case study for medical innovation as a whole, since they prevent diseases associated with obesity rather than obesity itself.
Statins might affect obesity through multiple channels. On the one hand, statin therapy reduces both the chance of contracting cardiovascular diseases and stroke, and the health consequences of these diseases [7] [8] [9] [10] [11] [12] . Since obesity is an important risk factor for these diseases, statin therapy likely reduces the health consequences of being obese. On the other hand, the effects of statins on health care costs are a priori ambiguous because of competing factors. By decreasing morbidity associated with obesity, statins plausibly diminish obesity-related costs at a given age. However, by increasing the length of life of obese people, statins enable accumulation of health care costs over more years. To our knowledge, no study has thus far attempted to quantify these effects of statins on obesity. In this study, we fill this gap in the literature and ask the following question: how did the introduction and widespread use of statins impact the health and health care costs of obesity?
To answer this question, we use the Future Elderly Model (FEM), an established dynamic microsimulation model of the health of Americans aged over 50 years [16] . Using the well-recognized estimates of the health impacts of statins, we construct an FEM scenario in which statins have not been discovered. By comparing life trajectories and medical costs for elderly Americans in this scenario and the baseline version of the FEM, we estimate the changes in the health and health care costs of obesity due to the introduction and widespread use of statins. We focus our analysis on the long-term impact of statins on life 1 Body mass index is defined as the ratio between the mass of individuals, expressed in kilograms, and the square of height, expressed in metres. 2 Authors' calculations with Medical Expenditure Panel Survey (MEPS) data. A MEPS respondent is defined as a statin user if he or she filled at least one prescription associated with the 'HMG-CoA reductase inhibitor' therapeutic subclass during a given year, or a prescription of Simcor, Advicor or Vytorin (which combine statins with other active ingredients). Therapeutic classes in the MEPS correspond to Multum Lexicon variables from Cerner Multum, Inc. expectancy, disability and health care costs, including total spending and spending by public programmes.
Methods

The Future Elderly Model
We conduct simulations using the FEM, a dynamic microsimulation model that follows Americans aged 51 years and older, and projects their health and medical spending over time. The FEM was initially developed by Goldman et al. [16] to forecast the implications of different medical technology scenarios on long-term health and health care costs. Its unique feature is that it follows the evolution of individual-level health trajectories rather than the average or aggregate health characteristics of a cohort. It has proved useful for a number of purposes in the recent past, including forecasting the future costs of cancer [17] and obesity [18] , and assessing the benefits of risk prevention [19] , the marginal cost of being obese [20] and the value of medical interventions for reducing its prevalence [14] .
The FEM simulates the lives of people from the age of 51 years onwards, using the Health and Retirement Survey (HRS), a biennial survey of the American population aged 51 years and over, which has been ongoing since 1992. The HRS data are used to compute the health transition models at the core of the FEM and the input population that goes into the simulations. It is supplemented by the Medical Expenditure Panel Survey (MEPS), a set of large-scale surveys of the non-institutionalized population of the USA, and the Medicare Current Beneficiary Survey (MCBS), a nationally representative survey of Medicare beneficiaries, to project health care spending and assess quality of life during the simulations. For each individual, the FEM takes into account initial demographic characteristics and health conditions to project medical spending, health conditions and behaviours, disability status and quality of life. We describe the model and methods briefly here; a complete technical appendix containing details on the modelling is provided in the Electronic Supplementary Material (ESM).
The FEM's core module calculates transition probabilities across various health states, including mortality, functional status and BMI, on the basis of the individual's current characteristics. These transition probabilities are modelled using first-order Markov processes, which depend on a battery of predictors: age, sex, education, race, ethnicity, BMI, smoking behaviour, marital status, employment, functional status and health conditions. We also control for baseline factors using a series of initial health variables.
Health conditions are derived from HRS survey questions and include diabetes, high blood pressure, heart disease, cancer (except for skin cancer), stroke or transient ischaemic attack, and lung disease (either chronic bronchitis or emphysema, or both). Transitions into illness and death are synthesized in Fig. 1 , which is analysed in further detail in ESM Appendix B. The concept of chronic conditions used in the simulations corresponds to having ever been diagnosed with a condition. We thus treat them as absorbing: once individuals receive a diagnosis, they are henceforth considered to have that condition. 3 The BMI variable is based on the self-reported height and weight of HRS respondents, and its evolution is projected with the estimates of a log-linear model. We adopt a log-linear specification to account for the 'thick' right tail of the BMI distribution in the HRS. We adjust for height and weight self-reporting biases, using the average BMI underreporting by age group and sex in the National Health and Nutrition Examination Survey (NHANES) data [21] . Functional status is measured by limitations in instrumental activities of daily living (IADLs), activities of daily living (ADLs) and residence in a nursing home. The IADL indicator is based on questions about difficulty using the phone, managing money and taking medications. The ADL indicator is based on respondents' assessment of their ability to perform basic tasks, such as dressing, eating and bathing. For the purpose of this study, we consider an individual as free of disability if he reported no IADL or ADL limitation and did not live in a nursing home; we consider him as disabled if he reported at least one IADL or ADL limitation but did not live in a nursing home; and we consider nursing home living as indicating the most severe functional status impairment. Unlike health conditions, we allow for transitions into and out of functional states.
To evaluate quality of life, we predict quality-adjusted life-years (QALYs) using the EQ-5D, a commonly used quality-of-life index based on five health-related variables 3 This interpretation is consistent with the Health and Retirement Survey (HRS) questionnaire, which asks respondents if they were ever diagnosed with a condition. addressing mobility, daily activities, self-care, anxiety, depression and pain. Using the MEPS data, we use an ordinary least squares regression to fit derived EQ-5D quality adjustment scores as a function of the chronic conditions and functional states included in the FEM simulations. This model is then used to predict the quality of each person's life-years in our simulations.
On the basis of two complementary medical spending data sources, a second FEM module predicts an individual's health spending with regard to health status (chronic conditions and functional status), demographics (age, sex, race, ethnicity and education), nursing home status and mortality. Our definition of medical costs includes medical provider visits, hospital events, inpatient stays, outpatient visits, emergency room visits, dental care, home health care, optometry, other medical equipment and services, prescribed medicines and nursing home stays. We separately predict total medical costs and medical costs paid for by the Medicare and Medicaid programmes. The estimates are based on pooled least squares regressions of each type of spending on risk factors, self-reported conditions and functional status, with spending inflated to current dollars, using the medical component of the Consumer Price Index.
Simulations
We simulate the health trajectories of elderly Americans characterized by a range of different BMIs and predict their health care costs with and without the possibility of using statins. These simulations focus on a representative cohort of Americans aged 51-52 years in 2010. For each period, the spending module predicts medical expenditure on the person's current state vector. Then, the health module predicts survival, health transitions, BMI, functional status and QALYs for the next period, 4 using the FEM's transition probabilities. The same process is repeated at each time step until everyone in the cohort has died.
Scenarios
The baseline FEM provides projections consistent with the current medical technology and thus implicitly includes the health effects and costs of statins. In the remainder of this article, we refer to the baseline FEM as the 'with statins' scenario. Our simulation strategy consists of comparing the predictions of the 'with statins' scenario with a scenario in which statins were never invented. We implement this 'without statins' scenario in two steps. First, we augment the FEM to identify individuals who currently use statins. Second, we remove the well-recognized health impact of statins from individuals identified as statin users. The differences in outcomes between the scenarios reveal the impact of statins.
Since there is no HRS question about statin use, we turn to MEPS Prescribed Medicine File data, which contain detailed information about prescription drugs and associated costs. Since statin use is a dichotomous variable, we use a probit model to estimate the probability that an individual is using a statin within the FEM simulations. We define an MEPS respondent as a statin user if he or she filled at least one prescription associated with the 'HMGCoA reductase inhibitor' therapeutic subclass 5 during a given year, or a prescription of Simcor, Advicor or Vytorin (which combine statins with other active ingredients).
The MEPS data reveal the dramatic increase in statin use over recent years. 6 To take these factors into account, we restrict our analysis to 2009-2011 MEPS data. This ensures that our statin use imputation is consistent with 2010, the first year of our simulations. More detail about this task and the results of our estimations are presented in ESM Appendix A.
The benefits of statin therapy in primary and secondary prevention of cardiovascular disease have been widely studied and well reported by many researchers. Table A1 in ESM Appendix C summarizes the most important findings from the recent literature.
As mentioned above, the 'without statins' scenario alters the FEM's health transition module to realistically remove the health benefits of statins from individuals who are identified as statin users by the simulations. For these individuals, we increase the probabilities of contracting diseases and mortality, using the inverse of the health effects of statins documented in Table A1 in ESM Appendix C:
1. Heart disease: We increase the probability of contracting heart disease by factors with a mean of 1.30. The distribution that is used corresponds to the inverse of the risk ratios of contracting a nonfatal 7 cardiovascular disease among the primary prevention population reported by the Taylor et al. [12] . 2. Stroke: We increase the probability of contracting a stroke by factors with a mean of 1.45, based on the Cochrane Collaboration's nonfatal stroke primary prevention result. 3. Mortality: The literature indicates that statins have differential mortality effects depending on sex and whether they are used for primary prevention or secondary prevention. We thus make the following adjustments:
(a) For individuals who have never been diagnosed with a stroke or a heart disease, we increase the mortality probability by factors with a mean of 1.16, based on the primary prevention risk ratios reported by the Cochrane collaboration. (b) For men and women who have been diagnosed with a heart disease, we increase the mortality probability by factors with means of 1.27 and 1.09, based on Gutierrez et al. [10] .
To account for uncertainty in statin effectiveness, we sampled new estimates of the clinical effect of statins from the confidence intervals of relative risks reported by the literature. Assuming parameters to be independent from each other, we drew 200 sets of risk ratio estimates from a All amounts are in present values at the age of 51 years, computed with a 3 % interest rate. BMI refers to 'body mass index' [defined as the ratio between the mass of individuals, expressed in kilograms, and the square of height, expressed in meters]. The first two columns present lifetime medical costs at the age of 51 years in the 'with statins' and 'without statins' scenarios. The third column presents the difference between the scenarios and corresponds to the additional medical costs due to the existence of statins. The last three columns decompose the additional costs due to statins by spending source. In the rows, we decompose medical costs by type (total medical costs excluding statin prescriptions and costs of statin prescriptions) and by functional status. A 'disabled' functional status refers to reporting at least one instrumental activity of daily living (IADL) or activity of daily living (ADL) limitation. The 'free of disability' status refers to reporting no IADL or ADL limitation and not living in a nursing home. 'In a nursing home' indicates the most severe functional status impairment. Confidence intervals for this table are presented in ESM Table A3 log-normal distribution and computed the factors described above. To obtain robust simulation results for each set of estimates, we ran 100 repetitions of the cohort simulations for each draw. We then computed and sorted the 200 means (one per draw) over these repetitions for all of our variables of interest. In the remainder of this article, the point estimates of our results correspond to the mean of each variable of interest across the 200 draws and their 100 repetitions. The bounds of the 95 % confidence intervals correspond to the fifth lowest and highest results for each variable of interest. These intervals can be interpreted as simulated 95 % confidence intervals with regard to the clinical uncertainty of the effectiveness of statins.
Isolating the Impact of Obesity
The key objective of this article is to isolate the difference in the impact of statins between otherwise identical healthy-weight individuals and obese individuals. A challenge in obtaining this differential impact arises because of the obesity gradient in the distribution of chronic conditions. For instance, the prevalence of diabetes and heart disease at the age of 51 years is significantly higher among the obese population than among the population with a healthy BMI.
To address this issue, we start by assigning a healthy BMI of 24.9 to each individual with a BMI C25 in our 2010 cohort, while keeping other states unchanged. We conduct simulations of our 'with statins' and 'without statins' scenarios for this healthy-weight cohort. We find the impact of statins on lifetime medical costs, length of life and quality of life associated with this BMI. We then repeat this process for BMIs of 30-40 by units of 5. The difference in the effect of statins obtained with one of these higher BMIs and the healthy weight reflects the marginal effect of statins for individuals of that BMI, since the distribution of health and economic statuses is otherwise identical. This strategy is outlined in Fig. 2 , and the effects of obesity and statin use on health are expanded upon in greater detail in ESM Appendix B. Overall, we expect obese individuals to benefit more from the existence of statins in the 'with statins' scenario and see their health deteriorate faster in the 'without statins' scenario. bars corresponds to the differential gain in life expectancy of statins for obese people (the difference-in-difference illustrated in Fig. 2 ). When compared with those of healthy-weight Americans, life expectancy gains are estimated to be 5-6 % (0.06-0.07 years) higher for people with obese BMIs. While these differences are modest, they are statistically significant 8 and support the notion that statins reduce the health consequences of obesity. We emphasize that these results do not mean that statins are not effective for obese people, but they mean that statins are almost as effective for people with a healthy BMI as they are for obese people.
Results
Effects of Statins on
As discussed in ESM Appendix B, as health evolves with the simulations, obese individuals are more likely to be ill and to benefit from the secondary mortality prevention effect of statins (i.e. after the onset of heart disease). In contrast, healthy-weight individuals are more likely to have never had a stroke or heart disease, and thus they likely benefit more from the primary prevention effects of statins. It therefore matters whether the life expectancy gains of Fig. 3 are in good health or with a disability.
To examine the composition of these gains, we decompose the additional life expectancy gains for obese individuals by functional status in Fig. 4 . The bars correspond to the difference-in-difference in life expectancy with a functional status due to both the existence of statins and to having an obese BMI. We find that the estimated additional gain in longevity for obese people is predominantly composed of time living with a disability. Difference-in-difference estimates of healthy life-years are either nonsignificant (for class 1 and 2 obesity) or significantly negative (for class 3 obesity).
Taken together, these estimates indicate that statins somewhat reduce the health cost of being obese as measured by life expectancy, but this gain mainly amounts to time in bad health.
Effects of Statins on Health Care Costs
Of course, by delaying the onset of chronic conditions and mortality, statins also impact medical costs. To quantify this impact, we computed the present value of the expected lifetime medical costs for our cohorts at the age of 51 years, discounted with a 3 % interest rate. The detailed results are shown in Table 1 .
Since medical costs in the MEPS and MCBS include prescription drugs, the direct cost of statin therapy is included in both the 'with statins' and 'without statins' projections. In 2010, according to MEPS data, the average annual cost of statin prescriptions for statin users aged over 51 years was $532. Of this amount, $125 and $26 were paid for by Medicare and Medicaid, respectively. For the 'with statins' scenario, we subtracted these values from the FEM's cost projections for all individuals identified as statin users in the simulations, and we reassigned them to the 'statins' row. For the 'without statins' scenario, we removed these costs altogether from the FEM's cost projections. 9 Our estimates indicate that statins have a modest impact of about $25,000-$30,000 on lifetime health care costs for individuals of all BMIs. Of this amount, 25 % stems from the direct costs of statin prescriptions, mainly paid for privately. The remainder corresponds to medical costs linked to the health benefits of statins. These notably arise because of the secondary prevention effect of statins, which enables individuals to live and require care longer after the onset of cardiovascular diseases. Thus, 60 % of the additional costs are incurred when individuals are disabled or are living in a nursing home. Nursing home living is the greatest contributor to the costs of statins and is largely paid for by the Medicaid programme. Overall, Medicare and Medicaid spending account for over half of the added costs.
While our estimates reveal a BMI gradient in the additional costs of statins, it is quite small: $2,800 for class 1 obesity, $3,500 for class 2 obesity and $4,000 for class 3 obesity. This gradient is consistent with the life expectancy gains described in Sect. 3.1 and indicate that statins increase the health care costs of being obese, albeit mildly.
Cost Effectiveness of Statins
In Table 2 , we compare the additional health care costs of statins with their health benefits. We consider total life expectancy gains (including time disabled or in a nursing home), disability-free life-years and QALYs. Again, our results show a BMI gradient, especially with regard to disability and quality of life. For instance, since individuals with class 3 obesity gain fewer healthy life-years and incur more costs, the estimated cost of statins per non-disabled life-year is $10,900 higher for them than for healthy-weight individuals. Despite this higher unit cost, we find that, for any reasonable value of life, statins are estimated to be quite cost effective for all health effectiveness measures and all BMIs. The patent expiration for atorvastatin in 2011 has likely increased the use of generics and further improved the cost effectiveness of statins. We expect that the patent expiration for rosuvastatin in 2016 will continue this trend.
According to MEPS data, 56.7 million Americans were aged 50 to 64 years in 2010. Of these, 34 % were obese and 26 % filled a statin prescription during the previous year. On the basis of our estimates, this cohort will have collectively lived 67.6 million life-years more than it would have if statins did not exist. Of these, 33.2 million years will be lived free of disability. These additional lifeyears gained will be associated with $1.5 trillion additional lifetime health care costs, for an average of $22,200 per life-year gained. Earlier, we saw that our estimates of life expectancy gains and costs of statins are modestly higher for obese individuals. When aggregated to the level of 2010's cohort aged 50 to 64 years, this gradient sums up to 9 By doing so, we assume that the direct costs of statin therapy for the elderly will be stable at their 2010 levels in the future. This is consistent with the remainder of the FEM's cost projections, which surmise that the costs of treatments remain proportional over time.
The 2010 values, however, constitute a higher bound for the future cost of statin prescriptions, given the patent expiration for atorvastatin in 2011 and the forthcoming patient expiration for rosuvastatin in 2016. The 2010 prescription costs are converted into 2009 dollars, the base year for the FEM's costs projections, using the US City Average Consumer Price Index (CPI) from the Bureau of Labor Statistics. The values in the table correspond to the difference in medical costs and life expectancy between the 'with statins' and the 'without statins' scenarios. Costs are in present values at the age of 51 years, computed with a 3 % interest rate. Disability-free life expectancy refers to reporting instrumental activity of daily living (IADL) or activity of daily living (ADL) limitations and not living in a nursing home. Quality-adjusted lifeyears (QALYs) adjust the length of life for quality on the basis of a person's chronic conditions and functional status. Ninety-five percent confidence intervals with regard to the uncertainty of the effectiveness of statins are presented in brackets. BMI body mass index 1.3 million additional life-years and $61 billion additional lifetime medical costs.
Effects of Statins on the Costs of Obesity
In the previous sections, we saw that the existence and widespread use of statins have large longevity and health impacts for both healthy-weight and obese individuals, contributing about 1 year to life expectancy at the age of 51 years. However, we noticed only a modest gradient of life expectancy (and lower QALY gains) with BMI, so it is unclear at this stage whether statins have a noticeable impact on the total costs of obesity. In other words, how do the additional longevity gains and medical costs of statins for obese people compare with the health and medical care costs of obesity?
In Table 3 , we present estimates of the total costs of obesity in both scenarios, accounting for both medical care and health costs. The medical care cost of being obese corresponds to the additional lifetime medical costs at the age of 51 years that can be expected when an individual moves from a healthy BMI to an obese BMI. 10 In panel A, our health cost concept refers to the loss in QALYs that can be expected when an individual moves from a healthy BMI to an obese BMI. We assign a value in 2009 dollars to this health cost by assuming a value of $150,000 per QALY [22] . In panel B, we conduct the same calculations with raw life expectancy losses, assuming a value of $100,000 per year.
In a world without statins, we estimate that 51-year-olds with class 1, 2 and 3 obesity would respectively incur $14,000, $21,000 and $25,800 higher lifetime health care costs than average healthy-weight individuals, and they could expect to live 1.9, 3.1 and 4.1 fewer QALYs. With our assumption of the value of QALYs, the total costs of 10 These are computed with the present values presented in Table 1 . For instance, the medical care cost of class 2 obesity in the 'with statins' scenario ($24.5) corresponds to the difference between the total medical costs in individuals with a body mass index (BMI) of 35 and those with a BMI \25 in the 'with statins' column ($485.5 and $460.9, respectively). In the 'with statins' scenario, the medical costs of obesity increase somewhat over the 'without statins' scenario, while the difference in QALYs between BMI categories remain mostly unchanged. This implies estimates of total costs of $303,700, $492,000 and $643,900 for class 1, 2 and 3 obesity, respectively.
The last rows show the difference in total costs due to the existence of statins. These values correspond to the difference-in-difference in health and medical care costs when considering both the existence of statins and obesity. Our estimates indicate that the availability of statins has no significant impact on the health care costs of class 1 and 2 obesity, and it increases the costs of class 3 obesity by $7,500 (1.2 % of the cost of obesity if statins did not exist). This occurs because statins are about as beneficial to the expected QALYs of individuals with all BMIs and they have a higher impact on the lifetime medical costs for obese individuals. The added costs stem from the additional time disabled gained by obese individuals, as illustrated in Fig. 4 .
In panel B, we replicate the calculations of panel A without accounting for quality of life. In this panel, all length-of-life lost due to obesity is valued equally at $100,000 per year. With this health cost concept, we find significantly positive effects of statins on the cost of class 1 and 2 obesity. These different findings reflect the reality that much of the difference in life expectancy gains for obese individuals is spent with some level of disability. For both health concepts, we find that the effect of statins is quite small relative to the cost of obesity.
Sensitivity Analyses
To further our understanding of the factors at play behind these results, we consider two sensitivity analyses for the effect of statins on the costs of obesity.
First, a plausible explanation for the small impact of statins on the cost of being obese is our very concept of the cost of obesity. In this paper, we reassigned the BMI of the FEM's nationally representative 2010 cohort to specific values and conducted separate simulations with these synthetic cohorts (as described in Sect. 2.2.2). We thus interpreted the costs of obesity as the health consequences and medical costs of trading a healthy BMI for an obese BMI at the age of 51 years, when other variables (including health) remain unchanged. An alternative interpretation would be that the costs of obesity should include comorbidities associated with obesity at the beginning of the simulations (higher prevalence of diabetes, hypertension, heart disease, etc.). Hypothetically, statins could have a larger impact under this interpretation. In ESM Appendix C1, we adopted this concept and conducted simulations without reassigning BMIs. While we found larger effects of statins on the life expectancy of obese individuals, these effects remain small relative to the costs of obesity.
Second, another factor that could be preventing statins from lowering the costs of obesity is their effectiveness for the primary prevention of diseases and mortality. Since healthy-weight individuals are more likely than obese individuals to avoid heart disease and stroke, they may benefit from primary prevention effects of statins over more years, while obese individuals benefit more from secondary prevention. To test this hypothesis, we conducted a second sensitivity analysis, in which we removed only the secondary prevention effects of statins in the 'without statins' scenario. This analysis is presented in ESM Appendix C2. Our results do show an increase in the differential effectiveness of statins with higher BMIs, which supports the notion that medical innovations aimed at preventing disease may be more beneficial to non-obese people. To significantly reduce the costs of obesity, innovations would thus need to treat, rather than prevent, disease. However, the differential effects of statins on life expectancy and quality of life for obese people remain small in comparison with the costs of obesity and are associated with higher medical costs. When taking both medical costs and health consequences into account, we do not find a significant net reduction in the total costs of obesity.
Overall, both analyses confirm the robustness of the small effect of statins on the costs of obesity.
Discussion
Obesity, given its high prevalence, impacts both individual health and the American fiscal outlook. As medical technology evolves over time, health outcomes for a number of obesity-related illnesses improve, changing the life outlook for obese people. In this article, we asked if such innovation could effectively alleviate the health and health care costs of obesity. We used statins-one of the most effective medical innovations of recent decades-as a case study.
In many ways, statins constitute a best-case scenario of medical innovations capable of reducing the burden of obesity. Statin therapy is inexpensive and has been shown to be quite effective in both preventing the onset of diseases for which obesity is a risk factor and decreasing their health impact.
Our main findings are fivefold. First, the current use of statins significantly extends life, with estimated gains in life expectancy at the age of 51 years of over 1 year for individuals with all BMIs. Second, life expectancy gains are modestly higher for obese individuals than for healthyweight individuals. Third, most of the additional gain in the life expectancy of obese people is lived in poor health, with at least some level of disability. Fourth, this additional time living with disability is associated with higher health care costs. Finally, when taking both quality of life and medical costs into account, our simulations indicate that statins have little or no effect on the costs of obesity.
Our study has several limitations. Notably, we do not take into account the potential moral hazard effect of statins in our 'without statins' scenario: by lowering the probability of contracting chronic diseases and reducing mortality, statins may reduce the incentive for preventive behaviour. In concept, the emergence of statins may explain some of the trend towards higher obesity rates, by lowering the health cost of being obese. A recent study revealed that the caloric intake and fat intake of statins users have indeed grown from 1999 to 2010. However, the study could not determine if the changes stemmed from expanded use of statins among people who eat more or from a change in the eating habits of statin users in response to the medical efficiency of statins [23] . In another recent study, Kaestner et al. [24] found that statin use is associated with conflicting behavioural responses. On the one hand, they found an increase in BMI and the probability of being obese among both men and women, as well as an increase in moderate or greater alcohol consumption. On the other hand, statin use leads to increased exercise rates among men. Overall, their results appeared to support a net substitution between the medical effectiveness of statins and healthy behaviours. If such responses were introduced into our model, they would reduce the health effectiveness of statins. Thus, our results can be viewed as an upper bound of the impact of statins on the costs of obesity.
Also, this study is based on the premise that the health effects of statins reported by the randomized clinical trial literature can be generalized to all statin users, regardless of the number of prescriptions filled during the year or their characteristics. In practice, the real-world effects of statins are bound to differ from those obtained in a clinical trial setting. However, observational research has shown that the effectiveness of statins in community practice is comparable to what has been observed in clinical trials [25] . Moreover, since the FEM does not include biomarker data, cholesterol levels do not directly contribute to the probability of mortality and contracting diseases in the simulation. Thus, even if the adjustments used in the 'without statins' scenario are correct, we may underestimate the probability of contracting diseases and mortality for individuals identified as statin users. Since this is true for both scenarios, and other key risk factors, such as diabetes and BMI, are included in the transition models, the bias in the difference between scenarios is likely to be small.
Finally, while we accounted for the clinical uncertainty of the effectiveness of statins, other sources of uncertainty are more difficult to correctly account for and were ignored. For example, there could also be changes over time in the mortality benefits of statin use as other treatments for clogged arteries and heart disease continue to improve, the medical care costs associated with various conditions and states will change over time, and transition probabilities between health states will also change over time with changes in medical technology. These are all reasons for caution when predicting the changes in lifetime costs associated with a given treatment. Thus, our results are indicative of the effect of the innovation of statins on lifetime outcomes when assuming that medical technology remains constant over time-which is, of course, unrealistic.
The results presented here refute the notion that because of the availability of statins and other medical innovations, people do not need to watch their weight as much as in the past. This is particularly true when taking factors such as quality of life and disability into account. Given these results, policymakers and practitioners should direct greater attention towards obesity prevention, as opposed to treatment of the consequences of obesity. This research should also serve as an example to researchers studying the economics of obesity of the difficulty of predicting the net effects on the costs of obesity from treatments that may, at first glance, seem to have obviously significant effects.
Conclusions
While our estimates indicate that the innovation of statins increased life expectancy at the age of 51 years by roughly 1.2 years, life expectancy gains have been only slightly greater for obese individuals than for individuals with a healthy BMI. The small marginal gain in life expectancy for obese individuals compared with non-obese individuals (0.06-0.07 years) was mostly associated with some level of disability. A similar story emerged with respect to lifetime health care costs. Statins increased health care costs by roughly $25,000-$30,000, but the marginal increase estimates for obese individuals compared with non-obese individuals was relatively small ($2,800-$4,000). Therefore, after valuing the quantity and quality of differences in life expectancy, we find that the innovation of statins has had little impact on the simulated cost of obesity (the sum of both health and health care costs). Statins significantly reduce the risks of heart disease, stroke and mortality, but because they do so for both obese and non-obese individuals, they have not significantly reduced the cost of obesity.
